Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers

Clinical Therapeutics

Volumn 28, Issue 9, 2006, Pages 1308-1317

  Shah, Jaymin ^a,d   Wesnes, Keith A ^b,c,d   Kovelesky, Rosemary A ^a,d   Henney III, Herbert R ^c,d  

^a ELAN PHARMACEUTICALS   (United States)

^b Cognitive Drug Research Ltd ^*  (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Aorda Therapeutics Inc   (United States)

Author keywords

bioavailability; formulation; pharmacodynamics; pharmacokinetics; tizanidine

Indexed keywords

TIZANIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; FOOD DRUG INTERACTION; FUNCTION TEST; HUMAN; HUMAN EXPERIMENT; MALE; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TABLET FORMULATION; VALIDATION STUDY; VOLUNTEER; XEROSTOMIA;

ADOLESCENT; ADULT; CAPSULES; CLONIDINE; COGNITION; CROSS-OVER STUDIES; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; FOLLOW-UP STUDIES; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXANTS, CENTRAL; REFERENCE VALUES; TABLETS;

EID: 33750044052     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.09.014     Document Type: Article

References (33)

1. Young R.R. Spasticity: A review. Neurology 44 Suppl 9 (1994) S12-S20
2. Wagstaff A.J., and Bryson H.M. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 53 (1997) 435-452
3. Davies J. Selective depression of synaptic transmission of spinal neurones in the cat by a new centrally acting muscle relaxant, 5-chloro-4-(2-imidazolin-2-yl-amino)-2,1, 3-benzothiodazole (DS103-282). Br J Pharmacol 76 (1982) 473-481
4. Collingridge G.L., and Davies J. Reversible effects of tetanus toxin on striatal-evoked responses and [3H]-gammaaminobutyric acid release in the rat substantia nigra. Br J Pharmacol 76 (1982) 403-411
5. Lapierre Y., Bouchard S., Tansey C., et al. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci 14 Suppl 3 (1987) 513-517
6. Nance P.W., Bugaresti J., Shellenberger K., et al., North American Tizanidine Study Group. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology 44 Suppl 9 (1994) S44-S51
7. United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 44 Suppl 9 (1994) S70-S78
8. Lataste X., Emre M., Davis C., and Groves L. Comparative profile of tizanidine in the management of spasticity. Neurology 44 Suppl 9 (1994) S53-S59
9. Wallace J.D. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 44 Suppl 9 (1994) S60-S69
10. Smith C., Birnbaum G., Carter J.L., et al., US Tizanidine Study Group. Tizanidine treatment of spasticity caused by multiple sclerosis: Results of a double-blind, placebocontrolled trial. Neurology 44 Suppl 9 (1994) S34-S43
11. Tse F.L., Jaffe J.M., and Bhuta S. Pharmacokinetics of orally administered tizanidine in healthy volunteers. Fundam Clin Pharmacol 1 (1987) 479-488
12. Mathias C.J., Luckitt J., Desai P., et al. Pharmacodynamics and pharmacokinetics of the oral antispastic agent tizanidine in patients with spinal cord injury. J Rehabil Res Dev 26 (1989) 9-16
13. Emre M., Leslie G.C., Muir C., et al. Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud). J Neurol Neurosurg Psychiatry 57 (1994) 1355-1359
14. Roberts R.C., Part N.J., Pokorny R., et al. Pharmacokinetics and pharmacodynamics of tizanidine. Neurology 44 Suppl 9 (1994) S29-S31
15. Granfors M.T., Backman J.T., Laitila J., and Neuvonen P.J. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br J Clin Pharmacol 57 (2004) 349-353
16. Koch P., Hirst D.R., and von Wartburg B.R. Biological fate of sirdalud in animals and man. Xenobiotica 19 (1989) 1255-1265
17. Granfors M.T., Backman J.T., Neuvonen M., and Neuvonen P.J. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2mediated presystemic metabolism. Clin Pharmacol Ther 76 (2004) 598-606
18. Granfors M.T., Backman J.T., Neuvonen M., et al. Fluvoxamine drastically increases concentrations and effects oftizanidine: A potentially hazardous interaction. Clin Pharmacol Ther 75 (2004) 331-341
19. [WMA Web site]. World Medical Association Declaration of Helsinki. Recommendations Guiding Medical Doctors in Bio medical Research Involving Human Subjects. Accessed June 15, 2005 (1989), WMA, Ferney-Voltaire, France. http://www.wma.net Accessed June 15, 2005
20. [EMEA Web site]. European Agency for the Evaluation of Medicinal Products. Accessed June 15, 2005. International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int Accessed June 15, 2005
21. Anonymous. Metropolitan height and weight tables. Stat Bull Metrop Life Found 64 (1983) 3-9
22. Guidance for Industry. Statistical Approaches to Establishing Bioequivalence (2001), US Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC
23. (Suppl). Wesnes K.A., Meulenberg O., Vermeij B., et al. The acute cognitive effects of amitriptyline, hydroxyzine and lorazepam in volunteers. J Psychopharmacol 10 (1996) A51
24. Wesnes K.A., Walker M.B., Walker L.G., et al. Cognitive performance and mood after a weekend on call in a surgical unit. Br J Surg 84 (1997) 493-495
25. Wesnes K.A., Garratt C., Wickens M., et al. Effects of sibutramine alone and with alcohol on cognitive func tion in healthy volunteers. Br J Clin Pharmacol 49 (2000) 110-117
26. Wesnes K.A., Ward T., McGinty A., and Petrini O. The memory enhancing effects of a Ginkgo biloba/Panax gin seng combination in healthy middleaged volunteers. Psychopharmacology (Berl) 152 (2000) 353-361
27. Wesnes K.A., McKeith I.G., Ferrara R., et al. Effects of rivastigmine on cognitive function in dementia with lewy bodies: A randomised placebocontrolled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord 13 (2002) 183-192
28. Kennedy D.O., Scholey A.B., and Wesnes K.A. The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology (Berl) 151 (2000) 416-423
29. Kennedy D.O., Scholey A.B., and Wesnes K.A. Differential, dose dependent changes in cognitive performance following acute administration of a Ginkgo biloba/Panax ginseng combination to healthy young volunteers. Nutr Neurosci 4 (2001) 399-412
30. Kennedy D.O., Scholey A.B., and Wesnes K.A. Dose dependent changes in cognitive performance and mood following acute administration of Ginseng to healthy young volunteers. Nutr Neurosci 4 (2001) 295-310
31. Bond A.J., and Lader M.H. The use of analogue scales in rating subjective feelings. Br J Med Psychol 47 (1974) 211-218
32. Zanaflex (tizanidine hydrochloride) [package insert] (2006), Acorda Therapeutics, Hawthorne, New York
33. Welling P.G. Interactions affecting drug absorption. Clin Pharmacokinet 9 (1984) 404-434